Navigation Links
Interleukin Genetics to Present at G-2 Reports' Molecular Diagnostic Conference
Date:2/2/2009

CEO Lewis Bender Shares Vision for Genetic Testing Industry

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that Chief Executive Officer Lewis H. Bender will speak at the Washington G-2 Reports' Business & Financial Strategies for Molecular Diagnostics conference, taking place February 2-4, 2009 in Fort Lauderdale, FL. The presentation is scheduled for Wednesday, February 4 at 8:30 a.m.

As part of his discussion, Mr. Bender will address the opportunities and challenges that exist within the genetic personalized health industry. The presentation will center on navigating genetic tests through consumer and physician channels from a regulatory, scientific and marketing standpoint, while providing a case study example to demonstrate their medical utility.

"The benefits of genetic testing across channels are significant," said Bender. "Not only can drug developers improve their probability of success in clinical trials by using genetic biomarkers to screen out non-responders, but consumers can use genetic tests to improve wellness by personalizing their diet, environment and lifestyle choices best suited for their genetic makeup."

Washington G-2 Reports' Molecular Diagnostics conference will provide expert insight and advice on how laboratories can and are successfully integrating molecular diagnostics into their business strategies, given the current regulatory business environment.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE: Alternext US: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
2. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
3. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
4. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
5. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
6. Interleukin-12 indicates survival prospects for melanoma patients
7. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
8. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
9. T cell immunity enhanced by timing of interleukin-7 therapy
10. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
11. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step company, ... Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, ... be presented by Captain Rommie Duckworth, LP, a career fire captain as well as ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... If you are thinking of a ... are interested in business architecture, October is the perfect time to visit. , Business Architecture ... an à la carte offering for individuals, as a 4-½ day package for individuals, and ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... label food ingredient solutions for the food and beverage industry offers Citri-Fi®, a ... ingredient statements during the purchasing decision process. As a result, labels need to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed the first ... of a mix of domestic and rest of world (ROW) authorized dealers specializing ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
(Date:5/4/2017)... , May 4, 2017 Clarius ... its wireless, handheld ultrasound scanners this week at ... Scientific Meeting (ACOG) in San Diego, ... "Clarius is the perfect tool for ... and heart rate, and evaluate pregnancy-related complications like ...
(Date:5/3/2017)... , May 3, 2017 A Catheterization ... hospital or healthcare facility. Commonly referred to as ... equipped with diagnostic imaging technology to give physicians ... heart. In these spaces, a team of physicians ... angioplasty, percutaneous coronary intervention, congenital heart defect closure, ...
Breaking Medicine Technology: